Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial
Abstract We compared the efficacy and safety of infliximab with intravenous immunoglobulin (IVIG), a standard therapy, in a phase 3 trial (NCT01596335) for Japanese patients with Kawasaki disease (KD) showing persistent fever after initial IVIG. Patients with initial IVIG-refractory KD, aged 1–10 ye...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2018
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/2e82f5bb7da04e2db25e2b012cdcb82a |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:2e82f5bb7da04e2db25e2b012cdcb82a |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:2e82f5bb7da04e2db25e2b012cdcb82a2021-12-02T15:08:19ZInfliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial10.1038/s41598-017-18387-72045-2322https://doaj.org/article/2e82f5bb7da04e2db25e2b012cdcb82a2018-01-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-18387-7https://doaj.org/toc/2045-2322Abstract We compared the efficacy and safety of infliximab with intravenous immunoglobulin (IVIG), a standard therapy, in a phase 3 trial (NCT01596335) for Japanese patients with Kawasaki disease (KD) showing persistent fever after initial IVIG. Patients with initial IVIG-refractory KD, aged 1–10 years, received a single dose of IV infliximab 5 mg/kg or IV polyethylene glycol-treated human immunoglobulin (VGIH) 2 g/kg on day 0. Primary outcome was defervescence rate within 48 h after the start of treatment. Safety was evaluated through day 56. Overall, 31 patients were randomized (infliximab, n = 16; VGIH, n = 15); 31.3% and 60.0% patients discontinued due to worsening KD. Defervescence rate within 48 h was greater with infliximab (76.7%) than VGIH (37.0%) (p = 0.023), and defervescence was achieved earlier with infliximab (p = 0.0072). Coronary artery lesions occurred in 1 (6.3%) and 3 (20.0%) patients receiving infliximab and VGIH, respectively, up to day 21. Adverse events occurred in 15 (93.8%) and 15 (100.0%) patients in the infliximab and VGIH groups, respectively. No serious adverse events in the infliximab group and one in the VGIH group were observed. Infliximab improved the defervescence rate within 48 h and time to defervescence versus standard therapy, and was well tolerated in patients with IVIG-refractory KD.Masaaki MoriTakuma HaraMasako KikuchiHiroyuki ShimizuTomoyuki MiyamotoSatoru IwashimaTatsuya OonishiKunio HashimotoNorimoto KobayashiKenji WakiYasuo SuzukiYoshikazu OtsuboHiroshi YamadaChikao IshikawaTaichi KatoShigeto FuseNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 8, Iss 1, Pp 1-10 (2018) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Masaaki Mori Takuma Hara Masako Kikuchi Hiroyuki Shimizu Tomoyuki Miyamoto Satoru Iwashima Tatsuya Oonishi Kunio Hashimoto Norimoto Kobayashi Kenji Waki Yasuo Suzuki Yoshikazu Otsubo Hiroshi Yamada Chikao Ishikawa Taichi Kato Shigeto Fuse Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial |
| description |
Abstract We compared the efficacy and safety of infliximab with intravenous immunoglobulin (IVIG), a standard therapy, in a phase 3 trial (NCT01596335) for Japanese patients with Kawasaki disease (KD) showing persistent fever after initial IVIG. Patients with initial IVIG-refractory KD, aged 1–10 years, received a single dose of IV infliximab 5 mg/kg or IV polyethylene glycol-treated human immunoglobulin (VGIH) 2 g/kg on day 0. Primary outcome was defervescence rate within 48 h after the start of treatment. Safety was evaluated through day 56. Overall, 31 patients were randomized (infliximab, n = 16; VGIH, n = 15); 31.3% and 60.0% patients discontinued due to worsening KD. Defervescence rate within 48 h was greater with infliximab (76.7%) than VGIH (37.0%) (p = 0.023), and defervescence was achieved earlier with infliximab (p = 0.0072). Coronary artery lesions occurred in 1 (6.3%) and 3 (20.0%) patients receiving infliximab and VGIH, respectively, up to day 21. Adverse events occurred in 15 (93.8%) and 15 (100.0%) patients in the infliximab and VGIH groups, respectively. No serious adverse events in the infliximab group and one in the VGIH group were observed. Infliximab improved the defervescence rate within 48 h and time to defervescence versus standard therapy, and was well tolerated in patients with IVIG-refractory KD. |
| format |
article |
| author |
Masaaki Mori Takuma Hara Masako Kikuchi Hiroyuki Shimizu Tomoyuki Miyamoto Satoru Iwashima Tatsuya Oonishi Kunio Hashimoto Norimoto Kobayashi Kenji Waki Yasuo Suzuki Yoshikazu Otsubo Hiroshi Yamada Chikao Ishikawa Taichi Kato Shigeto Fuse |
| author_facet |
Masaaki Mori Takuma Hara Masako Kikuchi Hiroyuki Shimizu Tomoyuki Miyamoto Satoru Iwashima Tatsuya Oonishi Kunio Hashimoto Norimoto Kobayashi Kenji Waki Yasuo Suzuki Yoshikazu Otsubo Hiroshi Yamada Chikao Ishikawa Taichi Kato Shigeto Fuse |
| author_sort |
Masaaki Mori |
| title |
Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial |
| title_short |
Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial |
| title_full |
Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial |
| title_fullStr |
Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial |
| title_full_unstemmed |
Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial |
| title_sort |
infliximab versus intravenous immunoglobulin for refractory kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial |
| publisher |
Nature Portfolio |
| publishDate |
2018 |
| url |
https://doaj.org/article/2e82f5bb7da04e2db25e2b012cdcb82a |
| work_keys_str_mv |
AT masaakimori infliximabversusintravenousimmunoglobulinforrefractorykawasakidiseaseaphase3randomizedopenlabelactivecontrolledparallelgroupmulticentertrial AT takumahara infliximabversusintravenousimmunoglobulinforrefractorykawasakidiseaseaphase3randomizedopenlabelactivecontrolledparallelgroupmulticentertrial AT masakokikuchi infliximabversusintravenousimmunoglobulinforrefractorykawasakidiseaseaphase3randomizedopenlabelactivecontrolledparallelgroupmulticentertrial AT hiroyukishimizu infliximabversusintravenousimmunoglobulinforrefractorykawasakidiseaseaphase3randomizedopenlabelactivecontrolledparallelgroupmulticentertrial AT tomoyukimiyamoto infliximabversusintravenousimmunoglobulinforrefractorykawasakidiseaseaphase3randomizedopenlabelactivecontrolledparallelgroupmulticentertrial AT satoruiwashima infliximabversusintravenousimmunoglobulinforrefractorykawasakidiseaseaphase3randomizedopenlabelactivecontrolledparallelgroupmulticentertrial AT tatsuyaoonishi infliximabversusintravenousimmunoglobulinforrefractorykawasakidiseaseaphase3randomizedopenlabelactivecontrolledparallelgroupmulticentertrial AT kuniohashimoto infliximabversusintravenousimmunoglobulinforrefractorykawasakidiseaseaphase3randomizedopenlabelactivecontrolledparallelgroupmulticentertrial AT norimotokobayashi infliximabversusintravenousimmunoglobulinforrefractorykawasakidiseaseaphase3randomizedopenlabelactivecontrolledparallelgroupmulticentertrial AT kenjiwaki infliximabversusintravenousimmunoglobulinforrefractorykawasakidiseaseaphase3randomizedopenlabelactivecontrolledparallelgroupmulticentertrial AT yasuosuzuki infliximabversusintravenousimmunoglobulinforrefractorykawasakidiseaseaphase3randomizedopenlabelactivecontrolledparallelgroupmulticentertrial AT yoshikazuotsubo infliximabversusintravenousimmunoglobulinforrefractorykawasakidiseaseaphase3randomizedopenlabelactivecontrolledparallelgroupmulticentertrial AT hiroshiyamada infliximabversusintravenousimmunoglobulinforrefractorykawasakidiseaseaphase3randomizedopenlabelactivecontrolledparallelgroupmulticentertrial AT chikaoishikawa infliximabversusintravenousimmunoglobulinforrefractorykawasakidiseaseaphase3randomizedopenlabelactivecontrolledparallelgroupmulticentertrial AT taichikato infliximabversusintravenousimmunoglobulinforrefractorykawasakidiseaseaphase3randomizedopenlabelactivecontrolledparallelgroupmulticentertrial AT shigetofuse infliximabversusintravenousimmunoglobulinforrefractorykawasakidiseaseaphase3randomizedopenlabelactivecontrolledparallelgroupmulticentertrial |
| _version_ |
1718388175608479744 |